Review article · 2017 · Open access

Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments

Volker Martin Lauschke, Lili A. Milani, Magnus Ingelman‐Sundberg

The AAPS Journal, 20(1), 4 · Published 27 November 2017 · DOI 10.1208/s12248-017-0161-x

Open PDFView at the publisherCite this paper

In brief

“Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments” is a 2017 review article by Volker Martin Lauschke and 2 co-authors, published in The AAPS Journal. OpenAlex counts 179 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at The AAPS Journal.

Citations
179
Most cited in
2021 (31)
Field-weighted impact
2.33
References
137
Authors
3

Abstract

Much of the inter-individual variability in drug efficacy and risk of adverse reactions is due to polymorphisms in genes encoding proteins involved in drug pharmacokinetics and pharmacodynamics or immunological responses. Pharmacogenetic research has identified a multitude of gene-drug response associations, which have resulted in genetically guided treatment and dosing decisions to yield a higher success rate of pharmacological treatment. The rapid technological developments for genetic analyses reveal that the number of genetic variants with importance for drug action is much higher than previously thought and that a true personalized prediction of drug response requires attention to millions of rare mutations. Here, we review the evolutionary background of genetic polymorphisms in drug-metabolizing enzymes, provide some important examples of current use of pharmacogenomic biomarkers, and give an update of germline and somatic genome biomarkers that are in use in drug development and clinical practice. We also discuss the current technology development with emphasis on complex genetic loci, review current initiatives for validation of pharmacogenomic biomarkers, and present scenarios for the future taking rare genetic variants into account for a true personalized genetically guided drug prescription. We conclude that pharmacogenomic information for patient stratification is of value to tailor optimized treatment regimens particularly in oncology. However, the routine use of pharmacogenomic biomarkers in clinical practice in other therapeutic areas is currently sparse and the prospects of its future implementation are being scrutinized by different international consortia.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Lauschke, V. M., Milani, L. A., & Ingelman‐Sundberg, M. (2017). Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments. The AAPS Journal, 20(1), 4. https://doi.org/10.1208/s12248-017-0161-x

MLA 9

Lauschke, Volker Martin, et al. “Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments.” The AAPS Journal, vol. 20, no. 1, 2017, p. 4. https://doi.org/10.1208/s12248-017-0161-x.

Chicago

Lauschke, Volker Martin, Lili A. Milani, and Magnus Ingelman‐Sundberg. 2017. “Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments.” The AAPS Journal 20 (1): 4. https://doi.org/10.1208/s12248-017-0161-x.

Harvard

Lauschke, V. M., Milani, L. A. and Ingelman‐Sundberg, M. (2017) ‘Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments’, The AAPS Journal, 20(1), p. 4. doi:10.1208/s12248-017-0161-x.

IEEE

V. M. Lauschke, L. A. Milani, and M. Ingelman‐Sundberg, “Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments,” The AAPS Journal, vol. 20, no. 1, p. 4, 2017, doi: 10.1208/s12248-017-0161-x.

BibTeX

@article{lauschke2017pharmacogenomic,
  title     = {{Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments}},
  author    = {Lauschke, Volker Martin and Milani, Lili A. and Ingelman‐Sundberg, Magnus},
  journal   = {The AAPS Journal},
  year      = {2017},
  volume    = {20},
  number    = {1},
  pages     = {4},
  doi       = {10.1208/s12248-017-0161-x},
  url       = {https://doi.org/10.1208/s12248-017-0161-x}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201711
20181515
20191515
20202525
20213131
20221919
20231818
20241818
20252020
20261616

Its field-weighted citation impact is 2.33: it has been cited 2.33 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • pharmacogenomic biomarkers
  • drug response variability
  • genetic polymorphism
  • drug-metabolizing enzymes
  • pharmacokinetics
  • pharmacodynamics
  • rare variants

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Lauschke, V. M., Milani, L. A., & Ingelman‐Sundberg, M. (2017). Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments. The AAPS Journal, 20(1), 4. https://doi.org/10.1208/s12248-017-0161-x

How many times has this paper been cited?

179 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The AAPS Journal: sign in and open the PDF from this page.

Who wrote this paper?

Volker Martin Lauschke, Lili A. Milani, Magnus Ingelman‐Sundberg.

What is the DOI of this paper?

10.1208/s12248-017-0161-x, permanently at https://doi.org/10.1208/s12248-017-0161-x. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.